ERBB2 and breast carcinoma: To specifically model the treatment cascade of Her2+ tumors following targeted therapy through dormancy and recurrence, a transgenic mouse model of Her2+/Neu driven breast cancer has been widely accepted as a clinically relevant model of dormancy23–25.